Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1Phase 2 1

Status

Withdrawn 1Terminated 1Recruiting 1

Sponsor Class

OTHER 1NIH 1NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 10Thoracic 6Tumor-Agnostic 5Genitourinary 4Sarcoma 3Gynecologic 3Lymphoid 2Head & Neck 2CNS 2Breast 2Other hematologic neoplasm 1Dermatologic 1

Conditions

Ovarian Neoplasms 52Fallopian Tube Neoplasms 48Endometrial Neoplasms 17Uterine Cervical Neoplasms 16Carcinoma, Ovarian Epithelial 15Brenner Tumor 15Carcinoma, Non-Small-Cell Lung 7Breast Neoplasms 7Esophageal Neoplasms 6Pancreatic Neoplasms 5Neoplasm Metastasis 5Endometrial Adenocarcinoma 5Stomach Neoplasms 4Melanoma 4Lung Neoplasms 4Triple Negative Breast Neoplasms 3Testicular Neoplasms 3Prostatic Neoplasms 3Peritoneal Neoplasms 3Neoplasms 3Carcinoma, Renal Cell 3Uterine Neoplasms 2Urinary Bladder Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Sarcoma 2Salivary Gland Neoplasms 2Recurrence 2Platinum-Refractory Fallopian Tube Carcinoma 2Ovarian Germ Cell Cancer 2

Interventions

Paclitaxel 28Carboplatin 28pembrolizumab 25Bevacizumab 14liposomal doxorubicin 12Cisplatin 11Gemcitabine 10Radiotherapy 8Drug Therapy 8Cyclophosphamide 8Blood Specimen Collection 8Topotecan 7Nivolumab 7olaparib 6Doxorubicin 6niraparib 5Therapeutics 5Dexamethasone 5pertuzumab 4pazopanib 4lenvatinib 4fludarabine 4cemiplimab 4atezolizumab 4Trastuzumab 4Surveys and Questionnaires 4Psychiatric Rehabilitation 4Polymerase Chain Reaction 4Fulvestrant 4Docetaxel 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Neoplasms × Taxes × Gynecologic × Clear all
NCT05256225 2026-05-27

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

National Cancer Institute (NCI)

Phase 3 Recruiting
360 enrolled
Gynecologic

Neoplasms, Endometrial Neoplasms

NCT00499291 2023-05-25

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Refractory Solid Tumors

Eastern Cooperative Oncology Group

Phase NA Withdrawn
BreastGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Teratoma, Testicular, Teratoma, Ovarian, Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Fallopian Tube Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Nasopharyngeal Neoplasms, Neoplasms, Neoplasms, Unknown Primary, Oropharyngeal Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Stomach Neoplasms, Teratoma, Testicular Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma

NCT00408070 2018-03-08

Bevacizumab Study With Carboplatin & Paclitaxel in Ovarian, Fallopian Tube or Primary Peritoneal Cancer

UConn Health

Phase 2 Terminated
5 enrolled 7 charts
Gynecologic

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡